晨光生物(300138) - 2022 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2022 was CNY 1,584,746,474.76, representing a 56.61% increase compared to CNY 1,011,910,611.71 in the same period last year[5]. - Net profit attributable to shareholders was CNY 106,924,931.52, up 37.00% from CNY 78,047,185.06 year-on-year[5]. - Basic and diluted earnings per share increased by 32.48% to CNY 0.2007 from CNY 0.1515 in the same period last year[5]. - Total operating revenue for the first quarter reached ¥1,584,746,474.76, a significant increase of 56.2% compared to ¥1,011,910,611.71 in the previous year[49]. - Net profit for the quarter was ¥106,869,101.26, representing a 37.5% increase from ¥77,680,503.48 year-over-year[49]. - The net profit attributable to the parent company was approximately ¥106.92 million, an increase from ¥78.05 million in the previous period, representing a growth of 37%[53]. - The total comprehensive income attributable to the parent company was approximately ¥102.53 million, compared to ¥80.63 million in the previous period, reflecting a growth of 27%[53]. Cash Flow - The net cash flow from operating activities was negative CNY 28,312,350.64, a decrease of 107.78% compared to CNY 364,115,945.78 in the previous year[5]. - Cash inflows from operating activities totaled approximately ¥1.85 billion, up from ¥1.18 billion in the previous period, indicating a growth of 57%[54]. - Cash outflows from operating activities amounted to approximately ¥1.88 billion, compared to ¥812.07 million in the previous period, resulting in a net cash flow from operating activities of approximately -¥28.31 million, down from ¥364.12 million[57]. - Cash inflows from financing activities were approximately ¥585.93 million, significantly higher than ¥62.67 million in the previous period, showing an increase of 834%[60]. - The net cash flow from financing activities was approximately -¥33.52 million, compared to -¥203.46 million in the previous period, indicating an improvement[60]. - The cash and cash equivalents at the end of the period were approximately ¥319.92 million, down from ¥377.32 million in the previous period[60]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 6,173,266,717.34, a 3.66% increase from CNY 5,955,165,411.81 at the end of the previous year[7]. - Total liabilities rose to ¥3,287,407,231.71, up from ¥3,171,782,359.89, indicating an increase of 3.6%[45]. - The company's total liabilities increased, with contract liabilities rising by 25.81% due to expanded sales activities[13]. Research and Development - Research and development expenses grew by 29.91%, reflecting the company's commitment to innovation and product development[14]. - Research and development expenses for the quarter were ¥17,432,842.73, up 30.5% from ¥13,419,264.15 in the previous year[49]. - The company is advancing several R&D projects, including improvements in chili red pigment production processes aimed at enhancing product yield and quality[32]. - The company is optimizing the production process for stevia and marigold, with the goal of achieving large-scale production to meet market demand[32]. - The company has completed the pilot test verification for the development of rutin products and is currently conducting summary analysis[35]. Market and Sales - The company experienced a 60.50% increase in cash received from sales of goods and services compared to the previous year[18]. - The sales volume of chili red pigment increased by over 30% year-on-year, with sales revenue growing by over 40% due to rising raw material costs[32]. - The sweet stevia sugar sales revenue exceeded 60 million yuan, achieving a year-on-year doubling in revenue[32]. - The health food business generated over 20 million yuan in revenue, leveraging the company's raw material and production advantages[32]. - The company is focusing on market expansion and risk control in its cottonseed business, with orderly progress in its New Third Board listing[32]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 12,306, with the largest shareholder holding 18.43%[21]. - The largest shareholder, Lu Qingguo, held 98,196,051 shares, with 73,647,038 shares pledged[24]. - The total number of restricted shares at the beginning of the period was 107,093,569, with 1,443,822 shares released during the period[28]. - The company has a commitment from certain executives not to transfer their shares for specified periods after leaving their positions[28]. Other Financial Metrics - The weighted average return on equity was 3.77%, up from 3.47% in the previous year, indicating improved profitability[5]. - Cash dividends and interest payments increased by 60.64% year-on-year, attributed to the growth in financing scale and corresponding interest expenses[19]. - The company reported a gross profit margin of approximately 13.5% for the quarter, compared to 12.2% in the same period last year[49]. - The total equity attributable to shareholders increased to ¥2,888,284,610.78 from ¥2,785,482,526.20, reflecting a growth of 3.7%[45].